Drug Database
CE

cerebroprotein hydrolysate for injection (III)

✓ Approved

ApicHope Pharmaceutical · 多肽类 · 多肽类

什么是 cerebroprotein hydrolysate for injection (III)?

cerebroprotein hydrolysate for injection (III) 是一种多肽类,由ApicHope Pharmaceutical研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)。

药物档案

公司ApicHope Pharmaceutical
药物类别多肽类
给药途径Injectable (Others)
状态Approved

治疗适应症

cerebroprotein hydrolysate for injection (III) 针对 3 个适应症,涉及 3 个治疗领域。

治疗领域疾病/病症分期
Nervous system disordersAmnesia✓ Approved
Injury, poisoning and procedural complicationsCraniocerebral injury✓ Approved
Psychiatric disordersAttention deficit hyperactivity disorder✓ Approved

相关研究文献

PubMedBMC urology2026-11-19

The double-decking method for rezūm water vapor therapy in benign prostatic hyperplasia: volumetric, functional, and dosimetric outcomes.

Tseng Ming-Jui MJ, Lo Ka-Lun KL, Wu Chi-Hsiang CH, Lin Shih-Ying SY et al.

Lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) significantly impact quality of life in aging men. Conventional Rezūm water vapor therapy consistently achieves only a modest 25-30% prostate volume reduction, leaving a clinically meaningful therapeutic gap-particularly for larger glands where single-plane periurethral injection fails to achieve adequate thermal coverage of the entire transition zone. To evaluate the efficacy and safety of a dual-layered injection strategy ("Double-decking method") for Rezūm water vapor therapy, targeting a treatment cycles per unit prostate volume (CPV) > 0.15, in patients with symptomatic BPH. Retrospective analysis of a prospectively maintained database of consecutive patients treated at a single institution. We enrolled 26 consecutive patients with symptomatic BPH (April 2025-December 2025) who underwent Rezūm therapy using the "Double-decking method," in which two sequential injections were performed within each field-of-view-one targeting the anterior and one the posterior aspect of the transition zone-targeting a CPV > 0.15. The primary endpoint was prostate volume (PV) reduction at 3 months; secondary endpoints included IPSS, Qmax, post-void residual (PVR), ejaculatory function assessed by the MSHQ-EjD, and erectile function assessed by the IIEF-5. The mean CPV was 0.19. Total prostate volume decreased by 50.7% (p < 0.001). Qmax improved by + 203.5% (p < 0.001), PVR decreased by 95.2% (p < 0.001), and IPSS declined by 77.2% (p < 0.001). All 7 catheter-dependent patients achieved catheter independence. MSHQ-EjD scores showed a statistically significant but clinically non-meaningful decline at 3 months (- 1.4 points; p = 0.003), below the MCID of 3 points. IIEF-5 scores showed no significant change at 3 months (- 0.1 points; p = 0.705), with no change in ED severity distribution. Grade II adverse events occurred in 4 patients (15.4%); no Grade ≥ III complications were observed. Subgroup analysis demonstrated consistent PV reduction across all volume categories (47.9-53.2%), with a significant between-group difference in Qmax (p = 0.013). A non-significant trend toward a plateau was observed beyond CPV ≈ 0.20. In this single-centre cohort, the Double-decking method was associated with substantial prostate volume reduction and a favorable safety profile through optimized dual-layered CPV delivery. A therapeutic window of CPV 0.15-0.20 is proposed as a hypothesis-generating observation requiring prospective validation. Not applicable (retrospective study).

PMID 43052957
阅读全文 →
PubMedJournal of hand therapy : official journal of the American Society of Hand Therapists2026-11-19

Barriers to post-stroke hand function recovery: A Delphi-based expert consensus on contributing factors and rehabilitation strategies.

Tiwari Prachi P, Mani Suresh S, Agarwal Nidhi N, Kohli Sunil S et al.

Post-stroke hand function impairment affects 60-70% of survivors at six months, persisting despite abundant guidelines that rarely differentiate protocols by Brunnstrom recovery stages-creating a critical gap in stage-specific guidance for Stage III challenges like synergistic overflow. To achieve expert consensus on primary barriers, neurophysiological mechanisms, and most effective rehabilitation strategies for hand function recovery in stroke survivors specifically at Brunnstrom Stage III. Modified three-round e-Delphi consensus study. Purposive sampling recruited 15 Indian neurorehabilitation experts (8 academicians with ≥10 years teaching/3 recent publications, 7 clinicians with ≥5 years experience/≥20% stroke caseload) from 50 invitees (30% response rate). Round 1 used three open-ended questions yielding 42 themes refined to 28 Likert-scale items (Supplementary Files S1-S2). Rounds 2-3 rated agreement (≥70%=strong consensus); thematic analysis and descriptive statistics (mean %, 95% CI) applied. Finger extensor weakness achieved highest consensus as primary barrier (81.2% mean agreement, 95% CI ±5.6%). Motor Relearning Program (MRP: 80.5%, ±4.9%) and Neurodevelopmental Therapy (NDT: 76.4%, ±5.4%) emerged as top strategies. Brunnstrom Stage III challenges (synergistic overflow, movement initiation: 67.2%, ±6.5%) reached moderate consensus; low-consensus items included robotics (38.7%) due to resource constraints. Muscle weakness-particularly finger extensors-dominates Stage III hand recovery barriers; MRP and NDT offer highest-priority interventions. Clinicians should prioritize stage-specific strengthening protocols over generic approaches, informing tailored guidelines for resource-limited settings. - Ethical approval for the study was granted by the Institutional Ethics Committee (Approval No. LPU/SOP/50/210527/15619/002).

PMID 43053507
阅读全文 →
PubMedJournal of orthopaedic surgery and research2026-11-19

Modified percutaneous vertebroplasty with bilateral cannulated screws and staged cement injection for stage I and II Kummell's disease: a mid-to-long term follow-up study.

Wang Huimin H, Li Xiaofeng X, Du Wei W, Sun Xuri X et al.

Kummell's disease (KD) is a delayed post-traumatic vertebral osteonecrosis often complicated by intravertebral vacuum cleft (IVC), cement loosening, and progressive vertebral collapse after conventional percutaneous vertebroplasty (PVP) or kyphoplasty. This study introduces a modified PVP technique using bilateral cannulated screws and staged cement injection for stage I and II KD, and evaluates its safety, feasibility, and mid-to-long-term clinical and radiological outcomes. A total of 38 patients with stage I (n = 18) or stage II (n = 20) KD were retrospectively enrolled. All underwent a modified procedure under local anesthesia: bilateral pedicle placement of headless cannulated screws, transmidline cement delivery using a steerable cannula (Ascend™), and staged injection (high-viscosity cement followed by low-viscosity cement). Clinical outcomes were assessed by visual analogue scale (VAS) and Oswestry Disability Index (ODI). Radiological outcomes included anterior vertebral height (AVH) and Cobb angle. Evaluations were performed preoperatively, at postoperative day 1, 6 months, 12 months, and at final follow-up (mean 17.2 months). Complications were recorded. Significant improvements were observed postoperatively and maintained throughout follow-up. VAS decreased from 6.89 ± 0.87 preoperatively to 1.26 ± 0.61 at final follow-up (P < 0.001). ODI improved from 69.58 ± 9.24% to 17.89 ± 7.03% (P < 0.001). AVH and Cobb angle were both significantly restored at day 1 and remained stable without progressive kyphosis or height loss. Cement extravasation occurred in 15.8% and adjacent vertebral fracture in 5.3%. Stage I patients received larger cement volume than stage II (6.83 ± 1.17 vs. 5.78 ± 1.12 mL, P = 0.008), but final outcomes did not differ between groups (all P > 0.05). The modified PVP combining bilateral cannulated screws, steerable cement delivery, and staged injection is safe and feasible for stage I and II KD. It provides sustained pain relief, functional improvement, and durable vertebral height and kyphosis correction, potentially preventing cement loosening and vertebral re-collapse.

PMID 43053120
阅读全文 →
PubMedSpinal cord2026-11-19

Correspondence to "Intramedullary injection of polymerized laminin in acute traumatic spinal cord injury: a first-in-human pilot study".

Nóbrega Paulo Ribeiro PR, da Rosa Rodrigo Fagundes RF, Pitombeira Milena Sales MS, de Souza Rodrigo Becco RB

PMID 43052361
阅读全文 →
PubMedNature nanotechnology2026-11-19

An extracellular contractile injection system for receptor-mediated protein delivery into plant cells.

Legendre Mark G MG, Muchenje Kimberley T KT, Heredia Andrés A, Colee Clair C et al.

Protein delivery into plant cells remains a major barrier in plant biotechnology. The Photorhabdus virulence cassette (PVC) is an extracellular contractile injection system, a phage tail-like bacterial nanomachine that naturally delivers proteins into insect host cells. Here we retargeted PVCs to plants by engineering their tail fibres to recognize the plant cell surface receptor FLAGELLIN SENSITIVE 2 (FLS2). We designed and characterized a library of FLS2-targeting PVCs and evaluated their ability to deliver native and non-native cargoes, including a fluorescent protein, Cre recombinase and R2 retroelement genome editor. Engineered PVCs delivered Cre into wild-type Arabidopsis thaliana and Nicotiana benthamiana protoplasts and leaf cells with efficiencies up to 16%. Delivery was FLS2 dependent and scaled with receptor abundance, reaching 75% of leaf cells in FLS2-overexpressing Arabidopsis. We further demonstrated the PVC-mediated delivery of R2 protein, resulting in the targeted insertion of a reporter gene into the plant genome and the expression of the integrated gene. This work establishes PVCs as a platform for receptor-mediated protein delivery into plant cells, laying the foundation for targeted and precise plant genetic engineering.

PMID 43052465
阅读全文 →
PubMedFuture science OA2026-11-19

Efficacy and safety of romiplostim in refractory aplastic anaemia: a plain language summary of phase II/III, multicentre, open-label study.

Jang Jun Ho JH, Mitani Kinuko K, Yoshizawa Shigeru S, Gamou Masaru M et al.

PMID 43053733
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多cerebroprotein hydrolysate for injection (III)